CoLucid Pharmaceuticals

Developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.

Launch date

2005

Employees

2-10 people

Market cap

Enterprise valuation

€873m (Public information from Jan 2017)

Durham North Carolina (HQ)

http://colucid.com

https://twitter.com/lillypad https://www.facebook.com/elilillyandco https://www.linkedin.com/company/colucid-pharmaceuticals-inc/

Date	Investors	Amount	Round
-	TVM Capital Life Science	N/A	-
Jan 2006	Triathlon Medical Venture Partners Pearl Street Venture Funds Domain Associates	$16.5m	Series A
Jul 2008	Triathlon Medical Venture Partners Pappas Capital Pearl Street Venture Funds Domain Associates Care Capital	$25.0m	Series B
Jan 2010	N/A	$9.2m	Early VC
Mar 2011	N/A	$2.0m	Debt
Aug 2011	Triathlon Medical Venture Partners Pappas Capital Pearl Street Venture Funds Domain Associates	$7.5m	Early VC
Jan 2015	Novo Ventures Auriga Partners Triathlon Medical Venture Partners Pappas Capital Pearl Street Venture Funds TVM Capital Healthcare Partners GmbH Domain Associates	$37.1m	Series C
May 2015	N/A	N/A	IPO
Jan 2017	N/A	$960m Valuation: $960m	Acquisition
Total Funding		€86.6m

Tech stackLearn more about the technologies and tools that this company uses.

CoLucid Pharmaceuticals

CoLucid Pharmaceuticals

Related Content

Recent News about CoLucid Pharmaceuticals

Tech stack